Compare MSEX & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSEX | NEO |
|---|---|---|
| Founded | 1897 | 2001 |
| Country | United States | United States |
| Employees | 395 | N/A |
| Industry | Water Supply | Precision Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2008 |
| Metric | MSEX | NEO |
|---|---|---|
| Price | $54.19 | $11.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $61.33 | $13.38 |
| AVG Volume (30 Days) | 91.1K | ★ 1.2M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.77% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.60 | $10.63 |
| Revenue Next Year | $10.94 | $9.73 |
| P/E Ratio | $22.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.94 | $4.72 |
| 52 Week High | $62.18 | $13.74 |
| Indicator | MSEX | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 63.35 | 73.67 |
| Support Level | $49.91 | $11.49 |
| Resistance Level | $54.92 | $12.60 |
| Average True Range (ATR) | 1.21 | 0.56 |
| MACD | 0.28 | 0.18 |
| Stochastic Oscillator | 94.71 | 95.11 |
Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.